AMR | The AMR Industry Alliance report provides a snapshot of the life science industry’s collective efforts in delivering on  commitments to tackle the rise of antimicrobial resistance (AMR). Results from the Alliance’s survey of biotech, diagnostics, generic and large research-based biopharmaceutical companies are mixed. Positive results include sustained investment in early R&D and diagnostics for AMR-related products (including antibiotics, antifungals, vaccines) and strides in responsible manufacturing of antibiotics. Worryingly, low levels of investment for later and more costly stages of R&D for AMR-related products may mean that promising early-stage compounds will never reach patients unless governments put in place new mechanisms and incentives for antibiotic development.